These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 29874335)

  • 1. S-1 monotherapy as second line chemotherapy in advanced gastric cancer patients previously treated with cisplatin/infusional fluorouracil [Retraction].
    Int J Clin Exp Pathol; 2016; 9(2):2755. PubMed ID: 29874335
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Multicenter phase III comparison of cisplatin/S-1 with cisplatin/infusional fluorouracil in advanced gastric or gastroesophageal adenocarcinoma study: the FLAGS trial.
    Ajani JA; Rodriguez W; Bodoky G; Moiseyenko V; Lichinitser M; Gorbunova V; Vynnychenko I; Garin A; Lang I; Falcon S
    J Clin Oncol; 2010 Mar; 28(9):1547-53. PubMed ID: 20159816
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Second-line chemotherapy of advanced disseminated gastric cancer after cisplatin, infusional 5-fluorouracil, folinic acid (PLF): benefit dependent on progression-free interval after first-line therapy.
    Stahl M; Müller C; Köster W; Wilke H
    Onkologie; 2005 Oct; 28(10):499-502. PubMed ID: 16160395
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Randomized phase II trial of infusional fluorouracil, epirubicin, and cyclophosphamide versus infusional fluorouracil, epirubicin, and cisplatin in patients with advanced breast cancer.
    Eisen T; Smith IE; Johnston S; Ellis PA; Prendiville J; Seymour MT; Walsh G; Ashley S
    J Clin Oncol; 1998 Apr; 16(4):1350-7. PubMed ID: 9552036
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Short-term efficacy of different chemotherapy regimens in the treatment of advanced gastric cancer: a network meta-analysis.
    Duo-Ji MM; Ci-Ren BS; Long ZW; Zhang XH; Luo DL
    Oncotarget; 2017 Jun; 8(23):37896-37911. PubMed ID: 28099947
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Randomised phase III trial of second-line irinotecan plus cisplatin versus irinotecan alone in patients with advanced gastric cancer refractory to S-1 monotherapy: TRICS trial.
    Nishikawa K; Fujitani K; Inagaki H; Akamaru Y; Tokunaga S; Takagi M; Tamura S; Sugimoto N; Shigematsu T; Yoshikawa T; Ishiguro T; Nakamura M; Morita S; Miyashita Y; Tsuburaya A; Sakamoto J; Tsujinaka T
    Eur J Cancer; 2015 May; 51(7):808-16. PubMed ID: 25797356
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Final results of a randomized phase III trial of sequential high-dose methotrexate, fluorouracil, and doxorubicin versus etoposide, leucovorin, and fluorouracil versus infusional fluorouracil and cisplatin in advanced gastric cancer: A trial of the European Organization for Research and Treatment of Cancer Gastrointestinal Tract Cancer Cooperative Group.
    Vanhoefer U; Rougier P; Wilke H; Ducreux MP; Lacave AJ; Van Cutsem E; Planker M; Santos JG; Piedbois P; Paillot B; Bodenstein H; Schmoll HJ; Bleiberg H; Nordlinger B; Couvreur ML; Baron B; Wils JA
    J Clin Oncol; 2000 Jul; 18(14):2648-57. PubMed ID: 10894863
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impacts of fluorouracil-metabolizing enzymes on the outcomes of patients treated with S-1 alone or S-1 plus cisplatin for first-line treatment of advanced gastric cancer.
    Koizumi W; Tanabe S; Azuma M; Ishido K; Nishimura K; Sasaki T; Nakatani K; Higuchi K; Nakayama N; Katada C
    Int J Cancer; 2010 Jan; 126(1):162-70. PubMed ID: 19588501
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Metronomic chemotherapy with 5-fluorouracil and cisplatin for inoperable malignant bowel obstruction because of peritoneal dissemination from gastric cancer.
    Yang S; Li S; Yu H; Li S; Liu W; Liu X; Ma H
    Curr Oncol; 2016 Jun; 23(3):e248-52. PubMed ID: 27330361
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adjuvant bi-weekly combination of cisplatin, infusional 5-fluorouracil and folinic acid followed by concomitant chemoradiotherapy with infusional fluorouracil for high risk operated gastric and gastroesophageal junction adenocarcinoma.
    Uncu D; Ozdemir NY; Aksoy S; Abali H; Oksuzoglu BC; Budakoglu B; Yildiz R; Aslan N; Zengin N
    Asian Pac J Cancer Prev; 2010; 11(6):1493-7. PubMed ID: 21338186
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of taxane monotherapy in advanced gastric cancer refractory to triplet chemotherapy with docetaxel, cisplatin, and S-1: a multicenter retrospective study.
    Iizumi S; Takashima A; Narita Y; Tajika M; Muro K; Kawai S; Yasui H; Matsushima T; Takahari D; Nagashima K; Boku N
    Cancer Chemother Pharmacol; 2017 Sep; 80(3):575-582. PubMed ID: 28730292
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The symptomatic benefit (the clinical benefit response) from the second-line chemotherapy in patients with advanced gastric adenocarcinoma.
    Sencan O; Buyukcelik A; Yalcin B; Boruban MC; Akbulut H; Demirkazik A; Senler FC; Onur H; Icli F
    Eur J Cancer Care (Engl); 2008 Jan; 17(1):26-32. PubMed ID: 18181888
    [TBL] [Abstract][Full Text] [Related]  

  • 13. ML17032 trial: capecitabine/cisplatin versus 5-fluorouracil/cisplatin as first-line therapy in advanced gastric cancer.
    Ryu MH; Kang YK
    Expert Rev Anticancer Ther; 2009 Dec; 9(12):1745-51. PubMed ID: 19954285
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The efficacy and toxicity of irinotecan with leucovorin and bolus and continuous infusional 5-fluorouracil (FOLFIRI) as salvage therapy for patients with advanced gastric cancer previously treated with platinum and taxane-based chemotherapy regimens.
    Kaya AO; Coskun U; Gumus M; Dane F; Ozkan M; Isıkdogan A; Alkis N; Buyukberber S; Yumuk F; Budakoglu B; Demirci U; Berk V; Bilici A; Inal A; Arpacı E; Benekli M;
    J Chemother; 2012 Aug; 24(4):217-20. PubMed ID: 23040686
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group.
    Van Cutsem E; Moiseyenko VM; Tjulandin S; Majlis A; Constenla M; Boni C; Rodrigues A; Fodor M; Chao Y; Voznyi E; Risse ML; Ajani JA;
    J Clin Oncol; 2006 Nov; 24(31):4991-7. PubMed ID: 17075117
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Randomized multicenter phase III study of a modified docetaxel and cisplatin plus fluorouracil regimen compared with cisplatin and fluorouracil as first-line therapy for advanced or locally recurrent gastric cancer.
    Wang J; Xu R; Li J; Bai Y; Liu T; Jiao S; Dai G; Xu J; Liu Y; Fan N; Shu Y; Ba Y; Ma D; Qin S; Zheng L; Chen W; Shen L
    Gastric Cancer; 2016 Jan; 19(1):234-44. PubMed ID: 25604851
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical Benefit and Health-Related Quality of Life Assessment in Patients Treated with Cisplatin/S-1 Versus Cisplatin/5-FU: Secondary End Point Results From the First-Line Advanced Gastric Cancer Study (FLAGS).
    Bodoky G; Scheulen ME; Rivera F; Jassem J; Carrato A; Moiseyenko V; Vynnychenko I; Prausová J; Van Laethem JL; Cascinu S; Ajani JA
    J Gastrointest Cancer; 2015 Jun; 46(2):109-17. PubMed ID: 25707610
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Infusional 5-Fluorouracil, Leucovorin and Docetaxel in Advanced Gastric Cancer.
    Kim YT; Sohn JH; Kim SH; Rha SY; Kim C; Roh JK; Kim BS; Jang WI; Chung HC
    Cancer Res Treat; 2003 Apr; 35(2):123-9. PubMed ID: 26680925
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bimonthly regimen of high-dose leucovorin, infusional 5-fluorouracil, epirubicin and cisplatin (modified ECF) as adjuvant chemotherapy in resected gastric adenocarcinoma.
    Unek IT; Unek T; Oztop I; Akman T; Atilla K; Ellidokuz H; Bora S; Sarioglu S; Yilmaz U
    Chemotherapy; 2012; 58(3):233-40. PubMed ID: 22832016
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oncolytic adenovirus Ad11 enhances the chemotherapy effect of cisplatin on osteosarcoma cells by inhibiting autophagy [Retraction].
    Am J Transl Res; 2020; 12(9):5992. PubMed ID: 33042475
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.